

From: [REDACTED]

Sent: 11 February 2010 17:14

To: Jennifer Heaton

Cc: [REDACTED]

Subject:RE: NSCLC - Gefitinib Appraisal Consultation Document

Dear NICE,

Thanks for giving us the opportunity to comment on this consultation document. We are not aware of any data that has not been included in this extensive analysis.

Whilst we acknowledge that there are ongoing discussions regarding the cost-effectiveness of first-line Gefitinib, we must not forget that for some patients, this treatment can offer very substantial improvements in both survival and quality of life, with minimal toxicity. We feel it would be a huge missed opportunity if such patients are to be denied this option in the future. Therefore we would encourage NICE to seek a place for this therapy in selected patients.

[REDACTED]

On behalf of the British Thoracic Society Lung cancer and Mesothelioma Specialist Advisory group